Present and potential future adjuvant issues in high-grade astrocytic glioma treatment

microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells

“…28 Notably, temozolomide brings significant therapeutic benefits in glioblastoma treatment and its cytotoxic activity is exerted through pro-autophagic processes. 29 In this work, we demonstrated that the modulation of miR-17 expression in GBM cells modulated the autophagic level. Specifically, ATG7 gene was identified as a molecular target of miR-17.…”

Glia to glioma: A wrathful journey

“…Novel but effective as the concept is, it depends on factors such as the choice of proper antigenic targets, good delivery system, effective antigen-presenting property and least side effects. Targeted immuno-therapeutic with combinational adjuvant therapies are showing a picture of prominence in this regard [146] .…”

A hypothesis and theoretical model speculating the possible role of therapy mediated neoplastic cell loss in promoting the process of glioblastoma relapse

“…The latter fact can be used as a strong argument against the belief that, GB cells which migrate away from the tumor mass and have efficient antiapoptotic and non-apoptotic death mechanisms, are mainly responsible for recurrences (Lefranc et al, 2009). While these mechanisms are quite likely to contribute towards recurrences, the close proximity between the sites of the initial tumor and relapse suggests that an intermixed population of neoplastic cells which survive therapy play a key role in recurrences.…”

“…The ability of glioblastoma (GBs) cells to escape away from the main tumor mass and their efficient anti-death mechanisms (apoptotic/non-apoptotic) are considered to be one of the main reasons behind recurrences that are responsible for the poor prognosis in these tumors (Lefranc et al, 2009). However, this fails to explain why most recurrences occur at or near the site of the initial tumor (Choucair et al, 1986).…”